Testing ENERGI-F705 for Parkinson's disease symptoms
Part of Brain & nervous system clinical trials.
This study tests a new tablet called ENERGI-F705 to see if it helps reduce Parkinson's disease symptoms and is safe to take. You'll need to have had Parkinson's for at least 2 years and be on standard Parkinson's medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40–75 years old
- Diagnosed with idiopathic Parkinson's disease (the common type) at least 2 years ago
- Currently taking standard Parkinson's medications with a stable dose for 12 weeks
- Taking at least 300 mg daily of levodopa equivalent (a common Parkinson's drug measurement)
- No major thinking difficulties (MMSE score of 24 or higher)
- Adequate liver, kidney, and blood cell counts at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication for people with early-onset Parkinson's disease. It aims to see if the drug safely improves motor symptoms and quality of life compared to a placebo.
This trial tests a new drug called VT-5006 to see if it is safe for people with Parkinson's disease. It focuses on those who have stomach or bowel issues, like constipation.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
This study tests whether an experimental medicine called SUL-238 can improve energy levels in the brain cells of people with early, untreated Parkinson's. It uses a special type of MRI to see if the medicine affects brain energy.
This study tests a new oral medication called EC5026 for Parkinson's disease. It aims to see if the drug is safe and if it might help control symptoms when added to your current levodopa treatment.
This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.